The cost of treating dyslipidaemia using National Cholesterol Education Program (NCEP) guidelines.
- 1 January 1998
- journal article
- review article
- Published by Springer Science and Business Media LLC in PharmacoEconomics
- Vol. 14 (3), 19-28
- https://doi.org/10.2165/00019053-199814003-00003
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study) fn1fn1This study was supported by Parke-Davis, Division of Warner Lambert Company, Morris Plains, New Jersey. Manuscript received August 20, 1997; revised manuscript received and accepted November 24, 1997.The American Journal of Cardiology, 1998
- The Cost of Reaching National Cholesterol Education Program (NCEP) Goals in Hypercholesterolaemic PatientsPharmacoEconomics, 1998
- Monotherapy with hMG-CoA reductase inhibitors and secondary prevention in coronary artery diseaseClinical Cardiology, 1996
- Cost-Effectiveness of Pravastatin in Secondary Prevention of Coronary Artery DiseaseThe American Journal of Cardiology, 1996
- The cost effectiveness of lipid lowering in Swedish primary health careJournal of Internal Medicine, 1996
- Costs and Effectiveness of Routine Therapy with Long-Term Beta-Adrenergic Antagonists after Acute Myocardial InfarctionNew England Journal of Medicine, 1988
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987
- Economic consequences of postinfarction prophylaxis with beta blockers: cost effectiveness of metoprolol.BMJ, 1987
- Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacinJournal of the American College of Cardiology, 1986
- COST‐BENEFIT ASPECTS OF POST‐MYOCARDIAL INFARCTION INTERVENTIONActa Medica Scandinavica, 1981